...in cash per Nucryst share owned. The deal follows the acquisition of substantially all of Nucryst's...

...its previously announced acquisition of substantially all of Nucryst's assets (see BioCentury, Nov. 16, 2009). Nucryst Pharmaceuticals Corp....

...Smith & Nephew will acquire substantially all of Nucryst's assets for $21 million in cash, plus...
...assets for $21 million in cash, plus the value of working capital. The sale includes Nucryst's...
...one preferred share redeemable for $1.77 in cash per Nucryst share owned. At June 30, Nucryst...

...bid price requirement for continued listing. The company has until March 15 to regain compliance. Nucryst Pharmaceuticals Corp....

...dressings in the EU for wound care. The products use Silcryst nanocrystalline silver coatings from Nucryst Pharmaceuticals Corp....

...also eliminated spending on undisclosed development programs until it secures commercialization partners for the programs. Nucryst's...
...is a nanocrystalline silver powder in development to treat Clostridium difficile infection. At March 31, Nucryst...
...million. At Dec. 31, 2008, the company had a 12-month operating loss of $6.1 million. Nucryst Pharmaceuticals Corp....

...Pharmacogenetics Hired: Eliot Lurier as CFO, formerly VP of finance and administration and CFO of Nucryst Pharmaceuticals Corp. WIR...

...32101 to treat IBD, but will continue to develop it to treat Clostridium difficile infection. Nucryst Pharmaceuticals Corp....